Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.

Farré M, Tomillero A, Pérez-Mañá C, Yubero S, Papaseit E, Roset PN, Pujadas M, Torrens M, Camí J, de la Torre R.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1637-49. doi: 10.1016/j.euroneuro.2015.05.007. Epub 2015 Jun 3.

PMID:
26073279
2.
3.

Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Peiró AM, Farré M, Roset PN, Carbó M, Pujadas M, Torrens M, Camí J, de la Torre R.

Psychopharmacology (Berl). 2013 Feb;225(4):883-93. doi: 10.1007/s00213-012-2894-7. Epub 2012 Nov 10.

PMID:
23142957
4.

Cilostazol in NICE guideline.

Bellmunt S, Roset PN, Escudero JR.

Heart. 2012 Jul;98(14):1107; author reply 1107-8. doi: 10.1136/heartjnl-2012-302092. Epub 2012 May 16. No abstract available.

PMID:
22591736
5.

Study of paracetamol 1-g oral solution bioavailability.

Farre M, Roset PN, Abanades S, Menoyo E, Alvarez Y, Rovira M, Baena A.

Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):37-41. doi: 10.1358/mf.2008.30.1.1159648.

PMID:
18389096
6.

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.

Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, de la Torre R.

J Pharmacol Exp Ther. 2007 Dec;323(3):954-62. Epub 2007 Sep 21.

PMID:
17890444
7.

[Study of the extent and rate of bioavailability of ibuprofen tablets].

Farré M, Roset PN, Pascual JA, Abanades S, Menoyo E, Alvarez Y, Baena A.

Reumatol Clin. 2005 Oct;1(3):155-60. doi: 10.1016/S1699-258X(05)72735-2. Epub 2008 Dec 20. Spanish.

8.

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers.

de la Torre R, Farré M, Mathúna BO, Roset PN, Pizarro N, Segura M, Torrens M, Ortuño J, Pujadas M, Camí J.

Eur J Clin Pharmacol. 2005 Aug;61(7):551-4. Epub 2005 Jul 23. No abstract available.

PMID:
16041599
9.

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Segura M, Farré M, Pichini S, Peiró AM, Roset PN, Ramírez A, Ortuño J, Pacifici R, Zuccaro P, Segura J, de la Torre R.

Clin Pharmacokinet. 2005;44(6):649-60.

PMID:
15910012
10.

Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine).

Pizarro N, Farré M, Pujadas M, Peiró AM, Roset PN, Joglar J, de la Torre R.

Drug Metab Dispos. 2004 Sep;32(9):1001-7.

PMID:
15319342
11.

Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J.

Ther Drug Monit. 2004 Apr;26(2):137-44. Review.

PMID:
15228154
12.

Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Farré M, de la Torre R, Mathúna BO, Roset PN, Peiró AM, Torrens M, Ortuño J, Pujadas M, Camí J.

Psychopharmacology (Berl). 2004 May;173(3-4):364-75. Epub 2004 Apr 8.

PMID:
15071716
13.

Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans.

Pacifici R, Pichini S, Zuccaro P, Farré M, Segura M, Ortuño J, Di Carlo S, Bacosi A, Roset PN, Segura J, de la Torre R.

J Pharmacol Exp Ther. 2004 Apr;309(1):285-92. Epub 2004 Jan 13.

PMID:
14722327
14.

Putting clinical pharmacology in context: the use of popular movies.

Farré M, Bosch F, Roset PN, Baños JE.

J Clin Pharmacol. 2004 Jan;44(1):30-6. Review.

PMID:
14681339
15.

Usefulness of sweat testing for the detection of MDMA after a single-dose administration.

Pichini S, Navarro M, Pacifici R, Zuccaro P, Ortuño J, Farré M, Roset PN, Segura J, de la Torre R.

J Anal Toxicol. 2003 Jul-Aug;27(5):294-303.

PMID:
12908943
16.

Modulation of the immune system in cannabis users.

Pacifici R, Zuccaro P, Pichini S, Roset PN, Poudevida S, Farré M, Segura J, De la Torre R.

JAMA. 2003 Apr 16;289(15):1929-31. No abstract available.

PMID:
12697794
17.

Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings.

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuño J, Menoyo E, Segura J, de la Torre R.

Ann N Y Acad Sci. 2002 Jun;965:421-33. Review.

PMID:
12105117
18.

Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis.

Pizarro N, Ortuño J, Farré M, Hernández-López C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, Camí J, de la Torre R.

J Anal Toxicol. 2002 Apr;26(3):157-65.

PMID:
11991532
19.

3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J, Torrens M, Camí J, de La Torre R.

J Pharmacol Exp Ther. 2002 Jan;300(1):236-44.

PMID:
11752122
20.

On-site testing of 3,4-methylenedioxymethamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users.

Pichini S, Navarro M, Farré M, Ortuño J, Roset PN, Pacifici R, Zuccaro P, Segura J, de la Torre R.

Clin Chem. 2002 Jan;48(1):174-6. No abstract available.

PMID:
11751553
21.

Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in humans.

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Ortuño J, Pujadas M, Bacosi A, Menoyo E, Segura J, de la Torre R.

Life Sci. 2001 Nov 2;69(24):2931-41.

PMID:
11720096
22.

Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males.

Roset PN, Farré M, de la Torre R, Mas M, Menoyo E, Hernández C, Camí J.

Drug Alcohol Depend. 2001 Nov 1;64(3):285-98.

PMID:
11672943
23.

Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH.

Navarro M, Pichini S, Farré M, Ortuño J, Roset PN, Segura J, de la Torre R.

Clin Chem. 2001 Oct;47(10):1788-95.

PMID:
11568088
24.

3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans.

Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de La Torre R.

Chem Res Toxicol. 2001 Sep;14(9):1203-8.

PMID:
11559034
25.

Sweat testing of MDMA with the Drugwipe analytical device: a controlled study with two volunteers.

Pacifici R, Farré M, Pichini S, Ortuño J, Roset PN, Zuccaro P, Segura J, de la Torre R.

J Anal Toxicol. 2001 Mar;25(2):144-6.

PMID:
11300507
26.

Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.

Pacifici R, Zuccaro P, Hernandez López C, Pichini S, Di Carlo S, Farré M, Roset PN, Ortuño J, Segura J, Torre RL.

J Pharmacol Exp Ther. 2001 Jan;296(1):207-15.

PMID:
11123382
27.

Pharmacology of MDMA in humans.

de la Torre R, Farré M, Roset PN, Lopez CH, Mas M, Ortuño J, Menoyo E, Pizarro N, Segura J, Cami J.

Ann N Y Acad Sci. 2000 Sep;914:225-37.

PMID:
11085324
28.

Immunomodulating activity of MDMA.

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Lopez CH, Ortuño J, Segura J, Camí J, de la Torre R.

Ann N Y Acad Sci. 2000 Sep;914:215-24. Review.

PMID:
11085323
29.

[Immunomodulator properties of ecstasy (MDMA)].

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Ortuño J, Segura J, Hernández-López C, De La Torre R.

Ann Ist Super Sanita. 2000;36(1):69-75. Review. Italian.

PMID:
11070610
30.

Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.

Cami J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R.

J Clin Psychopharmacol. 2000 Aug;20(4):455-66.

PMID:
10917407
31.

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, Camí J.

Br J Clin Pharmacol. 2000 Feb;49(2):104-9.

32.

Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study.

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Ortuño J, Segura J, de la Torre R.

Life Sci. 1999;65(26):PL309-16.

PMID:
10622275
33.
34.

Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Mas M, Farré M, de la Torre R, Roset PN, Ortuño J, Segura J, Camí J.

J Pharmacol Exp Ther. 1999 Jul;290(1):136-45.

PMID:
10381769
35.

Abuse liability of flunitrazepam among methadone-maintained patients.

Farré M, Terán MT, Roset PN, Mas M, Torrens M, Camí J.

Psychopharmacology (Berl). 1998 Dec;140(4):486-95.

PMID:
9888625
36.

[Toxicity of ecstasy].

Mas M, Farré M, Roset PN, Camí J.

Med Clin (Barc). 1998 Oct 24;111(13):516-7. Spanish. No abstract available.

PMID:
9859071
37.

Comment: use and abuse of flunitrazepam.

Mas M, Roset PN, Farré M, Camí J.

Ann Pharmacother. 1998 Sep;32(9):980-1. No abstract available.

PMID:
9762389
38.

[Bioavailability of medications].

Farré M, Roset PN, Mas M, Mas A.

Med Clin (Barc). 1998 Apr 25;110(14):558. Spanish. No abstract available.

PMID:
9646275
39.

Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism.

Farré M, de la Torre R, González ML, Terán MT, Roset PN, Menoyo E, Camí J.

J Pharmacol Exp Ther. 1997 Oct;283(1):164-76.

PMID:
9336321
40.

Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.

Farré M, Roset PN, Llorente M, Márquez M, Albet C, Pérez JA, Herrero E, Ortíz JA.

Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):343-50.

PMID:
9379783
41.

Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.

Muñoz-Navas M, Honorato J, Reina-Ariño M, Márquez M, Herrero E, Villamayor F, Torres J, Roset PN, Fíllat O, Camps F, Ortiz JA.

Arzneimittelforschung. 1997 Apr;47(4A):539-44.

PMID:
9205761
42.

Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.

Farré M, Roset PN, Badenas JM, Ugena B, Márquez M, Albet C, Herrero E, Ortiz JA.

Arzneimittelforschung. 1997 Apr;47(4A):528-30.

PMID:
9205758
43.

Long-term tacrine treatment in Alzheimer's disease.

Farré M, Roset PN.

Lancet. 1996 Oct 26;348(9035):1181-2. No abstract available.

PMID:
8888211

Supplemental Content

Loading ...
Support Center